References
- Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-4 https://doi.org/10.1136/jnnp.55.3.181
- Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 2001;57: 1497-9 https://doi.org/10.1212/WNL.57.8.1497
- de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinsons disease in Europe: the EUROPARKINSON collaborative study. European community concerted action on the epidemiology of Parkinsons disease. J Neurol Neurosurg Psychiatry. 1997;62:10-5 https://doi.org/10.1136/jnnp.62.1.10
- Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's disease striatum. Synapse. 1991;9:43-9 https://doi.org/10.1002/syn.890090107
- Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in caudate nucleus. J Neurochem. 1991;56:192-8 https://doi.org/10.1111/j.1471-4159.1991.tb02580.x
-
Booij J, Andringa G, Rijks LJ, Vermeulen RJ, De Bruin K, Boer GJ, et al. [
$^{123}I$ ]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTPlesioned monkeys. Synapse. 1997;27:183-90 https://doi.org/10.1002/(SICI)1098-2396(199711)27:3<183::AID-SYN4>3.0.CO;2-9 -
Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [
$^{123}I$ ]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62:133-40 https://doi.org/10.1136/jnnp.62.2.133 - Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with Iodine-123-FPCIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med. 1998;39:1879-84
-
Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, et al. Iodine-123-N-omega-fluoropropyl-2
$\beta$ -carbomethoxy- 3$\beta$ -(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med. 1998;39: 1143-8 -
Neumeyer JL, Wang SY, Milius RA, Baldwin RM, Zea-Ponce Y, Hoffer PB, et al.[
$^{123}I$ ]-2-$\beta$ -Carbomethoxy-3-$\beta$ -(4-iodo-phenyl)- tropane ($\beta$ -CIT). High affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem. 1991;34:3144-6 https://doi.org/10.1021/jm00114a027 -
Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [
$^{123}I$ ]-FP-CIT study group. Mov Disord. 2000;15: 503-10 https://doi.org/10.1002/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V - Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology. 2000; 55:1540-7 https://doi.org/10.1212/WNL.55.10.1540
-
Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, et al. Rate of progression in Parkinson's disease: a 6-[
$^{18}F$ ]fluoro-L-dopa PET study. Mov Disord. 2001;16:608-15 https://doi.org/10.1002/mds.1139 - Kaufman MJ, and Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum, Synapse. 1991;9;43-9 https://doi.org/10.1002/syn.890090107
- Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem. 1991;56:192-8 https://doi.org/10.1111/j.1471-4159.1991.tb02580.x
- Chui HC, Teng EL, Henderson VW, Moy AC. Clinical subtypes of dementia of the Alzheimer type. Neurology. 1985;35:1544-50 https://doi.org/10.1212/WNL.35.11.1544
- Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology. 1985;35:453-61 https://doi.org/10.1212/WNL.35.4.453
- Colloby S, O'Brien J. Functional imaging in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004;17: 158-63 https://doi.org/10.1177/0891988704267468
- Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry. 2002;73:134-40 https://doi.org/10.1136/jnnp.73.2.134
- Perneczky R, Msch D, Neumann M, Kretzschmar H, Mller U, Busch R, et al. The Alzheimer Variant of Lewy Body Disease: A Pathologically Confirmed Case-Control Study. Dement Geriatr Cogn Disord. 2005;20:89-94 https://doi.org/10.1159/000086472
-
Donnemiller E, Heilmann J, Wenning GK, Berger W, Decristoforo C, Moncayo R, et al. Brain perfusion scintigraphy with
$^{99m}Tc$ -HMPAO or$^{99m}Tc$ -ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med. 1997;24:320-5 https://doi.org/10.1007/BF01728771 -
Pizzolato G, Chierichetti F, Fabbri M, Cagnin A, Dam M, Ferlin G, et al. Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer [
$^{123}I$ ]-IBZM. Neurology. 1996;47:1065-8 https://doi.org/10.1212/WNL.47.4.1065 - Kemppainen N, Ruottinen H, Ngren K, Rinne JO. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology. 2000;55:205-9 https://doi.org/10.1212/WNL.55.2.205
- Ceravolo R, Volterrani D, Gambaccini G, Bernardini S, Rossi C, Logi C, et al. Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study. J Neural Transm. 2004;111: 1065-73. Epub 2004 Jun 18
- O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol. 2004;61:919-25 https://doi.org/10.1001/archneur.61.6.919
- Van Laere K, Casteels C, De Ceuninck L, Vanbilloen B, Maes A, Mortelmans L, et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med. 2006;47:384-92
- Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology. 2004;60:1568-72
- McKeith IG. Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin. 2000;18:865-902 https://doi.org/10.1016/S0733-8619(05)70230-9
- Kosaka K, Iseki E.: Diffuse Lewy body disease within the spectrum of Lewy body disease. In: Perry R, McKeith I, Perry E (eds): Dementia with Lewy Bodies. New York, Cambridge University Press, 1996, pp 238-47
-
Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC. [
$^{123}I$ ]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm. 2001;108:1011-9 https://doi.org/10.1007/s007020170019 -
Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [
$^{123}I$ ]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27:867-9 https://doi.org/10.1007/s002590000279 -
Nurmi E, Ruottinen HM, Kaasinen V, Bergman J, Haaparanta M, Solin O, et al. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [
$^{18}F ]CFT. Ann Neurol. 2000;47:804-8 https://doi.org/10.1002/1531-8249(200006)47:6<804::AID-ANA14>3.0.CO;2-F -
Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [
$^{18}F ]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314-9 https://doi.org/10.1136/jnnp.64.3.314 -
Morrish PK, Sawle GV, Brooks DJ. An [
$^{18}F ]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 1996;119:585-91 https://doi.org/10.1093/brain/119.2.585 - Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003;54: 93-101 https://doi.org/10.1002/ana.10609
-
Kim SE, Choi JY, Choe YS, Choi Y, Lee WY. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with
$^{123}I$ -beta-CIT SPECT. J Nucl Med. 2003;44:870-6 -
Jeon B, Kim JM, Jeong JM, Kim KM, Chang YS, Lee DS, et al. Dopamine transporter imaging with [
$^{123}I$ ]--CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psychiatry. 1998;65:60-4 https://doi.org/10.1136/jnnp.65.1.60 - Van Laere K, Casteels C, De Ceuninck L, Vanbilloen B, Maes A, Mortelmans L, et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using templatebased discriminant analysis. J Nucl Med. 2006;47:384-92
-
Wang J, Zuo CT, Jiang YP, Guan YH, Chen ZP, Xiang JD, et al.
$^{18}F -FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol. 2007;254:185-90 https://doi.org/10.1007/s00415-006-0322-9